Background {#Sec1}
==========

Thyroid cancer is the commonest malignancy of the endocrine system \[[@CR1]\]. Most primary thyroid cancers originate from the epithelial cells that line the thyroid follicles. There are four main types of thyroid carcinoma, namely, papillary, follicular, medullary and anaplastic. Langerhans cell histiocytosis (eosinophilic granuloma) is a rare disease, characterized by a wide range of clinical presentations including isolated lesions, multiple lesions or multi organ disseminated disease. The disease is characterized by hyperproliferation of Langerhans cells that share similarities with antigen-presenting Langerhans cells of mucosal sites, thymus, lymph nodes and skin \[[@CR2]\]. LCH does not arise from epidermal Langerhans cells, but from misguided myeloid dendritic cell precursors \[[@CR3]\]. The debate over whether LCH is a neoplasm or a reactive inflammatory disorder has been discussed over many years. Evidence of clonality in LCH was reported in 1994 and, thereby, it is currently considered as a neoplastic process \[[@CR2]\]. LCH may rarely involve the thyroid gland. Its association with PTC is also extremely rare, with only few case reports available in the literature \[[@CR1]--[@CR8]\]. Table [1](#Tab1){ref-type="table"} represents the cases of synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland \[[@CR1], [@CR2], [@CR7]--[@CR16]\]. Herein, we report a case of co-existing PTC and LCH in the thyroid gland with detected *BRAF V600E* and *V600K* mutations respectively.Table 1Reported cases of synchronous co-existing of PTC and LCH in the thyroid glandAuthor/YearSex/AgePTC&LCH In ThyroidSideLCH in other organsTreatmentBRAF mutationsFollow up (months)Goldstein N, 1991 \[[@CR9]\]F/31YesLeftBone, Pituitary gland, Lung, Skin, VaginaSurgery, Prednisone, Vincristine, Methotrexate, ChlorambucilNRDF (6)Saiz E, 2000 \[[@CR10]\]M/43YesLeftNoSurgeryNRDF(24)Foulet-Roge A, 2002 \[[@CR11]\]F/42YesLeftNoSurgeryNRDF (14)Burnett A, 2008 \[[@CR12]\]M/3LCH in Right, PTC in LeftBilateralLungSurgery, Prednisone, Mercaptopurine, MethotrexateNRNRJamaati HR, 2009 \[[@CR13]\]M/24YesBilateralLungSurgery, Etoposide, DexamethasoneNRDF(NR)Vergez S, 2010 \[[@CR1]\]M/29YesBilateralBone, Pituitary gland, Lung, SkinCorticosteroids, Vinblastine, Cladribine, ImatinibNRDRD(36)Chung DH, 2012 \[[@CR2]\]F/53YesRightNRSurgeryNRNRCeyran AB, 2014 \[[@CR14]\]M/37YesBilateralNRSurgeryNRDied due to Cardiac arrestGordon M S, 2016 \[[@CR16]\]F/22YesBilateralLabia VulvaSurgery, PrednisoneV600E in PTCNRAlzahrani R, 2016 \[[@CR7]\]F/27YesBilateralNoSurgery, CT PrednisoneNRNRWu X, 2017 \[[@CR8]\]M/40YesRightLung, LiverSurgery, CTNRDF(24)Jaimanti Bakshi JK,2018 \[[@CR15]\]M/31YesRightNoSurgery, Vinblastine and EtoposideNRNRCurrent caseF/37YesBilateralNoSurgery, Prednisone with EtoposideV600E in PTC,V600K in LCHDF (12)*F* female, *M* male, *CT* chemotherapy, *NR* not recorded, *DF* disease free, *DRD* death related disease

Case presentation {#Sec2}
=================

A 36-year-old woman was referred to the endocrine surgeon with a neck mass that gradually enlarged over a year. This mass was associated with dysphagia and complicated by skin sinus formation. There was no prior or family history of thyroid disease. Laboratory tests showed no evidence of thyroid hyper or hypo function.

Physical examination revealed a central neck skin sinus with a serosanguinous discharge (Fig. [1](#Fig1){ref-type="fig"}a). The thyroid gland was non-tender, diffusely enlarged, and extending bilaterally and retrosternally, mainly on the left side, with no cervical lymphadenopathy detected. Computerized tomography (CT) scan demonstrated a diffuse enlargement of the thyroid gland with skin infiltration, heterogeneous density and macrocalcification. The thyroid enlargement caused tracheal and esophageal compression and displaced neck vasculature laterally (Fig. [1](#Fig1){ref-type="fig"}b). Brain, chest, abdomen and pelvis CTs did not show any metastasis.Fig. 1Anterior midline neck sinus secondary to infiltrating thyroid cancer (**a**); CT scan transverse view: diffuse enlargement of thyroid gland infiltrating the skin with heterogeneous density (**b**)

FNA from the right thyroid lobe was interpreted as PTC. The decision was to go for total thyroidectomy with central neck dissection. Intraoperatively, the thyroid gland was extremely adherent to the surrounding structures with infiltration of the skin, strap muscles and both carotid sheaths, and extensively adherent to the esophagus and trachea. Consequently, only debulking thyroidectomy (isthmectomy) was performed along with sinus track excision and sampling of the central lymph node compartment.

The thyroid specimen was received fragmented and consisted of multiple pieces of firm brown-tan tissue, measuring 5.5 × 5 × 0.4 cm in aggregate. Also received was an ellipse of skin and a "central" lymph node, measuring 5x1x0.7 cm and 1.5 × 0.8x4cm, respectively. Microscopic examination of sections from the thyroid gland revealed a classical PTC (Fig. [2](#Fig2){ref-type="fig"}a). In addition, there were cells with eosinophilic cytoplasm and mild to moderately pleomorphic nuclei, some showing irregular contours or grooves, admixed with inflammatory cells including numerous eosinophils. These cells were seen in extensive sheets replacing 60--70% of the resected thyroid tissue as well as focally within the neoplastic papillary cores (Fig. [2](#Fig2){ref-type="fig"}b). Similar cell sheets were seen in sections of the skin and lymph node. Immunohistochemically, the papillary carcinoma stained positively for pan cytokeratin (CK) (Fig. [2](#Fig2){ref-type="fig"}c) and cytokeratin 19 (CK19) (data not shown), while the infiltrating mononuclear cells showed diffuse, strong reactivity for CD1a (Fig. [2](#Fig2){ref-type="fig"}d), CD43, S100 protein and were negative for myeloperoxidase, LCA and HMB45 immunostians (data not shown). The Ki67 proliferation index in these cells was around 60% (data not shown). The final diagnosis was synchronous PTC and LCH involving thyroid, overlying skin and cervical lymph node.Fig. 2Coexisting LCH and PTC. Focally extended to cores of PTC (inset, arrow), H&E × 400 (**a**); Sheets of LCH cells replacing thyroid parenchyma, H&E × 200 (**b**); PTC cells staining positively for panCK (arrow head); LCH cells are not stained (arrow), IHC × 400 (**c**); LCH cells staining positively for CD1a (arrow); PTC cells are not stained (arrow head), IHC × 100 (**d**)

Paraffin blocks including both the PTC and the LCH were manually macrodissected. DNA was automatically extracted and purified by QIAcube (Qiagen) from the two lesions separately using QIAamp DNA FFPE, while the concentration and purity of extracted DNA was assessed by Epoch-Bioteck. *BRAF* mutations were investigating using Easy BRAF kit (Diatech) that detects BRAF codon 600 mutations by real-time PCR (Rotor-Gene). DNA was assessed by analysis of the reaction controls (water, BRAF positive control) and analysis of BRAF control mix. The two DNA samples extracted from the two different lesions passed the assessment of DNA, and then were analyzed to search for mutations. Mutational analysis of *BRAF* for the DNA extracted from PTC and LHC revealed *V600E* and *V600K* mutations, respectively (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3*BRAF* gene mutations of LCH and PTC co-existing in the thyroid gland. Macrodissected LCH cells (marked red) from the thyroid gland (**a**); macrodissected PTC cells (marked red) from the thyroid gland (**b**); V600k BRAF mutation detected in the DNA extracted from LCH cells (**c**); V600E BRAF mutation detected in the DNA extracted from PTC cells (**d**); PC: positive control; NC: negative control

The postoperative course was uneventful. The patient received palliative chemotherapy, at her home country, that consisted of Etoposide with Prednisone. After twelve months of follow-up, the patient is in a stable clinical condition.

Discussion and conclusions {#Sec3}
==========================

LCH has a broad spectrum of clinical presentations and may rarely involve the thyroid gland. There is probably some association between LCH and PTC, as few cases of LCH co-existing with PTC have been previously described in the English literature (Table [1](#Tab1){ref-type="table"}).

Activating *BRAF* mutations is an important event in the development of PTC \[[@CR17], [@CR18]\]. *BRAF V600E* mutation has been reported in about 40--60% of patients with PTC \[[@CR19]\]. A somatic activating *BRAF V600E* mutation has also been identified in approximately 60% of LCH, strongly supporting the neoplastic rather than inflammatory nature of LCH \[[@CR20]\]. However, no sufficient information is available in the literature, regarding the *BRAF* mutation status of cases of co-existing LCH and PTC \[[@CR1]\]. It has been speculated that the *BRAF V600E* mutation in LCH could lead to PTC through creating a microenvironment that is appropriate for neoplastic transformation \[[@CR4]\]. To the best of our knowledge, our case is the first report of *BRAF* mutations in tissues of a LCH and a PTC co-existing in the thyroid gland, suggesting an aggressive disease and etiologic relation between the two conditions that involves the *BRAF* gene. Since the patient decided to start the treatment at home country, there was limitation in the patient follow-up. Our case is the second case reported to harbor *BRAF V600K* mutation in LCH \[[@CR21]\]. The PTC was not iatrogenically induced as the patient did not receive any prior radiotherapy \[[@CR22]\], while LCH patients showed improvement after chemotherapy \[[@CR8]\].

The co-existence of LCH with an otherwise classical PTC may lead to a clinical impression of an aggressive, locally advanced type of thyroid cancer. This may affect the selection of surgical management. This was our experience in the present case in which only debulking thyroidectomy was attempted to relieve the compressive symptoms, as total thyroidectomy was not possible due to widespread local extension and the involvement of vital surrounding structures.

The clinical behavior of LCH is extremely variable. Some cases are limited in extent and follow an indolent course, whereas others exhibit multi organ involvement, frequent recurrences, and are refractory to conventional therapy. The presence *BRAF V600E* mutation was shown to be associated with high-risk features and poor response to chemotherapy in children with LCH \[[@CR23]\]. Clinically and histologically, our case exhibited features suggestive of an aggressive behavior, namely, an extensively infiltrative pattern, lymph node involvement and a high Ki67 proliferation index.

In conclusion, co-existing PTC and LCH in the thyroid gland is extremely rare. The demonstration of *BRAF* mutations in tissues obtained from both lesions suggests an etiologic relation between the two conditions and opens the door for further studies to investigate a possible etiologic connection between LCH and PTC.

The co-existence of BRAF mutated-LCH with an otherwise classical PTC may lead to a clinical impression of an aggressive, locally advanced type of thyroid cancer. This may have an impact on the surgical procedure selection, as well as post-surgical treatment.
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:   Computerized tomography
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:   Fine needle aspiration
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:   Papillary thyroid carcinoma
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